Panbela Therapeutics, Inc. (PBLA)
USD 0.26
(-3.7%)
USD 0.26
(-3.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -51.29 Million USD | -47.56% |
| 2022 | -34.76 Million USD | -227.56% |
| 2021 | -10.61 Million USD | -106.1% |
| 2020 | -5.14 Million USD | -16.47% |
| 2019 | -4.42 Million USD | -1.75% |
| 2018 | -1.76 Million USD | 27.76% |
| 2017 | -6.01 Million USD | -16.43% |
| 2016 | -5.16 Million USD | 4.97% |
| 2015 | -5.11 Million USD | -8693.56% |
| 2014 | -75.39 Thousand USD | 63.01% |
| 2013 | -194.32 Thousand USD | -157.94% |
| 2012 | 289.44 Thousand USD | 384.45% |
| 2011 | -101.4 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -7.19 Million USD | -12.05% |
| 2024 Q2 | -7.85 Million USD | 1.6% |
| 2023 Q3 | -15.69 Million USD | -165.52% |
| 2023 FY | - USD | -47.56% |
| 2023 Q1 | -5.01 Million USD | -9.77% |
| 2023 Q2 | -5.91 Million USD | -17.94% |
| 2023 Q4 | -6.42 Million USD | 59.08% |
| 2022 Q2 | -22.13 Million USD | -499.46% |
| 2022 Q1 | -3.69 Million USD | -11.24% |
| 2022 FY | - USD | -227.56% |
| 2022 Q4 | -4.56 Million USD | -4.44% |
| 2022 Q3 | -4.37 Million USD | 80.25% |
| 2021 FY | - USD | -106.1% |
| 2021 Q2 | -2.37 Million USD | -0.17% |
| 2021 Q4 | -3.31 Million USD | -30.46% |
| 2021 Q3 | -2.54 Million USD | -7.16% |
| 2021 Q1 | -2.37 Million USD | -125.5% |
| 2020 Q2 | -455 Thousand USD | 75.87% |
| 2020 Q4 | -1.05 Million USD | 40.18% |
| 2020 Q3 | -1.75 Million USD | -286.15% |
| 2020 Q1 | -1.88 Million USD | -79.45% |
| 2020 FY | - USD | -16.47% |
| 2019 Q4 | -1.05 Million USD | 32.67% |
| 2019 Q3 | -1.56 Million USD | -31.29% |
| 2019 Q2 | -1.18 Million USD | -92.08% |
| 2019 Q1 | -619 Thousand USD | 29.1% |
| 2019 FY | - USD | -1.75% |
| 2018 Q1 | -1.3 Million USD | 27.69% |
| 2018 FY | - USD | 27.76% |
| 2018 Q4 | -873 Thousand USD | 10.74% |
| 2018 Q3 | -978 Thousand USD | 23.35% |
| 2018 Q2 | -1.27 Million USD | 2.45% |
| 2017 Q4 | -1.8 Million USD | -73.28% |
| 2017 Q1 | -1.99 Million USD | 5.63% |
| 2017 Q2 | -1.16 Million USD | 41.73% |
| 2017 Q3 | -1.04 Million USD | 10.15% |
| 2017 FY | - USD | -16.43% |
| 2016 Q4 | -2.11 Million USD | -86.17% |
| 2016 FY | - USD | 4.97% |
| 2016 Q2 | -948 Thousand USD | 2.67% |
| 2016 Q3 | -1.13 Million USD | -19.73% |
| 2016 Q1 | -974 Thousand USD | 20.68% |
| 2015 Q2 | -79.44 Thousand USD | -5.02% |
| 2015 FY | - USD | -8693.56% |
| 2015 Q4 | -1.22 Million USD | -59.48% |
| 2015 Q3 | -770 Thousand USD | -869.25% |
| 2015 Q1 | -75.64 Thousand USD | -145.12% |
| 2014 Q3 | -84.47 Thousand USD | -83.57% |
| 2014 FY | - USD | 63.01% |
| 2014 Q2 | -46.01 Thousand USD | 53.51% |
| 2014 Q1 | -98.98 Thousand USD | -1060.84% |
| 2014 Q4 | 167.65 Thousand USD | 298.48% |
| 2013 Q3 | -47.04 Thousand USD | -24.88% |
| 2013 Q2 | -37.67 Thousand USD | 44.5% |
| 2013 FY | - USD | -157.94% |
| 2013 Q4 | -8527.00 USD | 81.87% |
| 2013 Q1 | -67.87 Thousand USD | -153.47% |
| 2012 FY | - USD | 384.45% |
| 2012 Q3 | 84.03 Thousand USD | -17.93% |
| 2012 Q4 | 126.93 Thousand USD | 51.06% |
| 2012 Q1 | -24.92 Thousand USD | 0.0% |
| 2012 Q2 | 102.39 Thousand USD | 510.88% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -11367.677% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -73.843% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 55.027% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -225.449% |
| Better Therapeutics, Inc. | -38.26 Million USD | -34.06% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -34.049% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -186.773% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -52.059% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -53.699% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 51.766% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -5515.273% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -57.915% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -9.856% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -802.468% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -214.664% |
| Molecular Templates, Inc. | 1.43 Million USD | 3686.993% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -269.684% |
| NexImmune, Inc. | -28.16 Million USD | -82.103% |
| Orgenesis Inc. | -60.71 Million USD | 15.521% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -69767.604% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -217.703% |
| Scopus BioPharma Inc. | -11.71 Million USD | -337.918% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 90.5% |
| Statera Biopharma, Inc. | 38.93 Million USD | 231.743% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -645.119% |
| Trevena, Inc. | -35.28 Million USD | -45.358% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -91413.086% |
| Vaccinex, Inc. | -19.74 Million USD | -159.743% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -4799.243% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | -9.458% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -606.236% |